Alnylam Stock Is Running Its Own Race. Here’s What That Means for Your Portfolio.

The biotech’s recent strength is tempting, but its real value lies in a long-term pattern of moving independently from the market you already own.

In a week where the S&P 500 slid 2.9%, Alnylam Pharmaceuticals (ALNY) stood out by climbing 4.0%. That kind of divergence gets noticed. It’s the financial equivalent of a bright green shoot in a parched field, and it triggers a powerful instinct in any investor: the urge to pile into the one thing that’s working.

That impulse is completely natural. But chasing a few days of performance is often a fast track to buying high and selling low. The question that actually determines your long-term wealth isn’t where Alnylam stock will be next week. It’s about what owning it does for your entire portfolio. How much of its return is a genuinely different story from the broad market you likely already own through an index fund, and how should you size it?

A Genuinely Differentiated Return Stream

To answer that, we have to look past a single week of trading to the multi-year data. Over the last five years, Alnylam’s stock has had a correlation of just 0.31 with the S&P 500. In simple terms, this means the majority of its performance has been driven by its own specific business, its clinical trials, drug approvals, and sales growth, not by the daily tides lifting and lowering the overall market.

For a portfolio, that’s an attractive profile. It’s a source of potential growth that doesn’t just mirror the returns you’re already getting from an index fund. And Alnylam has paired this independence with results, delivering an annualized return of 17.7% over the past five years, compared to 13.5% for the S&P 500. It’s been running its own race and winning it.

The Price of Independence: Sizing for Volatility

This independence doesn’t make it a sleepy, defensive stock. In fact, its behavior suggests the opposite. Over the past year, on days the S&P 500 fell, Alnylam absorbed about 62% of the market’s loss. On days the market rose, it captured about 44% of the gain. This isn’t a flaw; it’s a feature of a high-octane biotech stock whose fate is tied more to its own pipeline than to economic cycles.

This means it’s a holding to size with care. It’s not a stabilizer that will cushion your portfolio on rough days. Instead, it’s an asset that adds a different dimension of risk and reward, one that demands a thoughtful allocation rather than an impulsive, oversized position based on a hot week.

Behind the Numbers: A Biotech Powering Ahead

That independent return is backed by a business hitting a new gear. On its latest earnings call, Alnylam announced its “first quarter exceeding $1 billion in product revenue,” a major milestone. This was powered by its TTR franchise, which targets a rare disease and generated $910 million in the first quarter alone. The company is seeing strong commercial execution, with patient adherence to its key drug, AMVUTTRA, exceeding 90%.

This strong execution has earned the stock a premium price-to-earnings ratio of 68.5, reflecting its trailing revenue growth of 82.6%. That valuation bakes in high expectations for continued success, and the company’s ability to deliver will depend on navigating an evolving competitive landscape for its core drugs.

Instead of chasing this week’s rally, the disciplined move is to see Alnylam for what the numbers show it is: a valuable, differentiated return engine for a portfolio, sized with respect for its inherent volatility. The one signal to watch isn’t the daily stock price, but the sales trajectory of AMVUTTRA in the next earnings report.

So How Should You Hold A Stock Like Alnylam Pharmaceuticals?

Owning a strong performer is one thing; holding it in a way that fits the rest of your portfolio is another. The job is to size each position to the return it adds and the volatility it carries, so a single hot name never comes to dominate the risk you are taking. The Trefis High Quality (HQ) Portfolio is built on exactly that discipline, pairing the upside of strong businesses with the stability of a 30-stock portfolio, rebalanced with intent, and a track record of outperforming the S&P 500, S&P Mid-cap, and Russell 2000. Building a portfolio around how assets actually behave together, rather than which one ran hardest last week, is how you grow wealth while smoothing the ride.